⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081256 | 1.00 | — | — | |
| SCHEMBL168922 | 1.00 | — | — | |
| SCHEMBL4556846 | 1.00 | — | — | |
| SCHEMBL248268 | 0.97 | — | — | |
| SCHEMBL4556830 | 0.97 | — | — | |
| SCHEMBL409268 | 0.90 | — | — | |
| SCHEMBL4557090 | 0.90 | — | — | |
| SCHEMBL414445 | 0.83 | — | — | |
| SCHEMBL4557221 | 0.75 | CXCR4 (0.33) | — | |
| SCHEMBL36141 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176212-B2 | 2,4-diamino pyrimidine compounds having anti-cell proliferative activity | ASTRAZENECA AB (SE) | 2007-02-13 | — | — | US | claimed |
| EP-1107957-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-10-18 | — | — | EP | claimed |
| EP-1107958-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-16 | — | — | EP | claimed |
| US-20050090493-A1 | 2,4-Diamino pyrimidine compounds having anti-cell proliferative activity | ASTRAZENECA AB | 2005-04-28 | — | — | US | claimed |
| US-6632820-B1 | Anticancer agents | ASTRAZENECA AB (SE) | 2003-10-14 | — | — | US | claimed |
| EP-1107957-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-20 | — | — | EP | claimed |
| EP-1107958-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-20 | — | — | EP | claimed |
| WO-2000012486-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | claimed |
| WO-2000012485-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | claimed |
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| EP-1713781-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-7176212-B2 | 2,4-diamino pyrimidine compounds having anti-cell proliferative activity | ASTRAZENECA AB (SE) | 2007-02-13 | — | — | US | disclosed |
| EP-1713781-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| EP-1107957-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| EP-1107958-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| EP-1055683-A1 | NOVEL ACETAMIDE DERIVATIVE AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000012486-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012485-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
| EP-0936216-A1 | NOVEL ACETAMIDE DERIVATIVES AND PROTEASE INHIBITORS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1999-08-18 | — | — | EP | disclosed |